Do you have a question or suggestion?

Fill out the form and we will contact you as soon as possible. Thank you for your interest!

     

     

    Main Contacts  Pro EuroDILINet

    General enquiries: info@proeurodilinet.eu


    Dr Raul ANDRADE
    Chair

    Prof Guruprasad AITHAL
    Vice Chair

    Dr Rossella MAGLI
    Science officer

    Ms Nathalie WARENGHIEN
    Administrative officer

    Dr. Michael Merz

    Dr. Michael Merz

    WORKING GROUP 2. DILI RISK STRATIFICATION

    Deputy for Leader WG2 (michael.merz@t-online.de)

    University Hospital Zurich (Switzerland)

     

    • Clinical Pharmacologist and Drug Safety Expert
    • 1993-1998: Quintiles Research, Freiburg, Germany
    • 1998-2017: Novartis Pharma AG, Basel, Switzerland
      • Head Modeling and Simulation, Clinical Pharmacology
      • Global Safety Profiling Director, Exploratory Clinical Development
      • Section Head Systems Toxicology & Head Safety Networks, Translational Sciences
      • Chair investigative Liver Expert Team, Novartis Institutes for BioMedical Research
    • 2010-2016: Project coordinator IMI SAFE-T consortium for clinical safety biomarker qualification
    • Since 05/2017: Independent consultant, focus on Drug-Induced Liver Injury; Consortium Coordinator at University Hospital Zürich, Switzerland
    • In charge of proposal H2020-JTI-IMI2-2017-13-two-stage: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease